The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / GI Disease in Early Systemic Sclerosis Associated with Worse Outcomes

GI Disease in Early Systemic Sclerosis Associated with Worse Outcomes

March 5, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Although researchers continue working to understand the pathophysiology of systemic sclerosis (SSc), evidence suggests SSc is mediated by vasculopathy, immunologic dysregulation and fibrosis. Given this evidence, it comes as no surprise studies have documented that 5–8% of SSc patients develop severe gastrointestinal (GI) disease. Moreover, independent associations appear to exist between severe GI disease, higher skin scores and telangiectasia. Reinforcing the association is the fact complications from GI dysmotility may be associated with anti-cardiolipin antibody (ACA) positivity.

You Might Also Like
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
  • Systemic Sclerosis Mortality Rate May Be Underestimated
Also By This Author
  • Smart, Stem Cell-Based Implants May Revolutionize the Treatment of Arthritis

These observations led Nicolas Richard, MD, a rheumatology fellow at Hopital Maisonneuve-Rosemont, Montreal, Canada, and colleagues to examine the incidence, predictors and outcomes associated with severe GI disease in a large inception SSc cohort. They found many patients with early SSc experience severe GI disease and the GI disease was associated with significant morbidity and increased mortality. The results of their research were published online in Rheumatology.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study cohort comprised 556 patients (Canadians and Australians) with SSc who had a disease duration of less than two years. The investigators followed these patients for a mean of 4.3±3.0 years and used physician reports, as opposed to objective verification, to document the presence of severe GI disease. The researchers found almost 10% of subjects developed severe GI disease at two years and more than 15% of subjects developed severe GI disease by the fourth year.

Patients with severe GI disease had markers of muscle inflammation, skin fibrosis and vasculopathy. Inflammatory arthritis and fecal incontinence was also associated with severe GI disease. In addition to the high incidence of severe GI disease, 58.3% of patients developed malabsorption, 19.4% developed hyperalimentation and 27.8% developed pseudo-obstruction during follow up.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Over the course of the study, 19.4% of subjects with severe GI disease and 14.5% of patients without severe GI disease died. When the investigators adjusted for age and sex, they found severe GI disease was associated with a greater than two-fold increase in the risk of death. When the investigators examined the health-related quality of life of the 311 Canadian patients who completed 1,132 visits with Medical Outcomes Study Short Form-36 (SF-36) data, they found severe GI disease was associated with a worse health-related quality of life.

“Our results not only show an increased risk of mortality, but also an association with significant impairment in [health-related quality of life],” write the authors in their discussion. “Other studies have also shown an influence of GI involvement on health-related quality of life in SSc, and our study confirms these findings for subjects with severe GI involvement using a generic measure of health status. Using robust methodology accounting for bias due to missing data, we were able to assess the independent relationship between the presence of severe GI disease and both physical and mental health status impairment.”

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: gastrointestinal, gastrointestinal disease, Outcomes, Systemic sclerosis

You Might Also Like:
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
  • Systemic Sclerosis Mortality Rate May Be Underestimated
  • Research Underscores Need to Assess Oral Health in Patients with Systemic Sclerosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)